Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Appropriate specifications at the IND stage

J Geigert1

  • 1IDEC Pharmaceuticals Corporation, San Diego, California, USA.

PDA Journal of Pharmaceutical Science and Technology
|March 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Appropriate specifications at the IND stage.

Developments in biological standardization·1997
Same author

Development and shelf-life determination of recombinant human granulocyte--macrophage colony-stimulating factor (LEUKINE, GM-CSF).

Pharmaceutical biotechnology·1996
Same author

Role of quality control in validation of biopharmaceutical processes: case example of clean-in-place (CIP) procedure for a bioreactor.

PDA journal of pharmaceutical science and technology·1994
Same author

Development and shelf-life determination of recombinant interleukin-2 (proleukin).

Pharmaceutical biotechnology·1993
Same author

Overview of the stability and handling of recombinant protein drugs.

Journal of parenteral science and technology : a publication of the Parenteral Drug Association·1989
Same author

The long-term stability of recombinant (serine-17) human interferon-beta.

Journal of interferon research·1988

Setting early-stage biopharmaceutical product specifications requires careful consideration of available data. This discussion explores practical approaches to establishing appropriate specifications during Investigational New Drug (IND) trials.

Area of Science:

  • Biopharmaceutical Science
  • Drug Development
  • Regulatory Affairs

Background:

  • Biopharmaceutical product specifications must be scientifically sound and appropriate.
  • Early-stage clinical development (Investigational New Drug - IND trials) presents challenges in establishing robust product specifications.
  • Industry practices may involve excessive testing or setting unrealistic specifications due to external or internal pressures.

Purpose of the Study:

  • To discuss practical strategies for setting product specifications for biopharmaceutical products.
  • To address the challenges of establishing specifications during the early IND stages of clinical development.
  • To guide biopharmaceutical companies in developing scientifically sound and appropriate product specifications.

Main Methods:

Related Experiment Videos

  • Review of current industry practices and challenges in setting biopharmaceutical product specifications.
  • Discussion of the adequacy of test data available at the IND stage.
  • Analysis of the pressures influencing specification setting.

Main Results:

  • The abstract does not contain specific results but presents a discussion of challenges.
  • Identifies potential pitfalls such as the 'must do every test' syndrome.
  • Highlights the risk of setting unrealistic specifications that require later justification for loosening.

Conclusions:

  • Practical product specifications for biopharmaceutical products are crucial at the IND stage.
  • A balanced approach is needed to avoid excessive testing and unrealistic targets.
  • Effective specification setting supports successful biopharmaceutical product development.